Hypofractionated accelerated radiochemotherapy with cytoprotection (chemo-hypoARC) for inoperable non-small cell lung carcinoma

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3625-3631

  Koukourakis, Michael I ^a,d   Patlakas, George ^b   Froudarakis, Marios E ^a   Kyrgias, George ^c   Skarlatos, John ^c   Abatzoglou, Ioannis ^a   Bougioukas, George ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Komotini General Hospital   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

^d DUTh ^*  (Greece)

Author keywords

Acceleration; Amifostine; Chemotherapy; Hypofractionation; Non small cell lung cancer; Radiotherapy

Indexed keywords

AMIFOSTINE; ANTIHISTAMINIC AGENT; CORTISONE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; OXALIPLATIN; PARACETAMOL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TROPISETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; FIBROSIS; HUMAN; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RASH; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AMIFOSTINE; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CYTOPROTECTION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 35349000093     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stove, D, Strawn JR, Turrisi AT and Somerfield MR; American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
2. Curran WJ: New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology 63(Suppl 2): 29-38, 2002.
3. Trodella L, D'Angelillo RM, Ramella S, Ciresa M and Massaccesi M: Dose fractionation and biological optimization in lung cancer. Rays 29: 319-326, 2004.
4. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T and Byhardt R: Randomized trial of amifostine in locally advanced non-small cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23: 2145-2154, 2005.
5. Saunders MI, Rojas A, Lyn BE, Pigott K, Powell M, Goodchild K, Hoskin PJ, Phillips H and Verma N: Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small cell lung cancer. Br J Cancer 78: 1323-1328, 1998.
6. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A and Yannakakis D: The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 34: 315-322, 1996.
7. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E and Harris AL: endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727-735, 2006.
8. Macejewski B, Taylor JM and Wither HR: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7: 323-326, 1986.
9. Koukourakis MI, Abatzoglou I, Sivridis L, Tsarkatsi M and Delidou H: Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 26: 2437-2443, 2006.
10. Boccia R, Anne PR, Bourhis J, Brizel D, Daly C, Holloway N 3rd, Hymes S, Koukourakis M, Kozloff M, Turner M and Wasserman T: Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 60: 302-309, 2004.
11. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N and Helidonis ES: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521, 1999.
12. Baillet F, Maulard C, Dessard-Diana B, Manoux D, Housset M, Alapetite C, Michel-Langlet P and Delanian S: Curative radiotherapy of unresectable bronchial cancer. Apropos of 266 cases without metastasis with 4 to 6 years follow-up (oat cell carcinoma excluded). Ann Med Interne (Paris) 140: 353-355, 1989.
13. Slotman BJ, Njo KH, de Jonge A, Meijer OW and Karim AB: Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer 72: 1885-1893, 1993.
14. Stevens MJ and Begbie SD: Hypofractionated irradiation for inoperable non-small cell lung cancer. Australas Radiol 39: 265-270, 1995.
15. Devereux S, Hatton MQ and Macbeth FR: Immediate side effects of large fraction radiotherapy. Clin Oncol (R Coll Radiol) 9: 96-99, 1997.
16. Plataniotis GA, Kouvaris JR, Dardoufas C, Kouloulias V, Theofanopoulou MA and Vlahos L: A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC): effective palliation and patients' convenience. Lung Cancer 35: 203-207, 2002.
17. Cross CK, Berman S, Buswell L, Johnson B and Baldini EH: Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58: 1098-1105, 2004.
18. Sundstrom S, Bremnes R, Aasebo U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM and Kaasa S: Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 22: 801-810, 2004.
19. Cheung PC, Yeung LT, Basrur V, Ung YC, Balogh J and Danjoux CE: Accelerated hypofractionation for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54: 1014-1023, 2002.
20. Thirion P, Holmberg O, Collins CD, O'Shea C, Moriarty M, Pomeroy M, O'Sullivan C, Buckney S and Armstrong J: Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformai radiation therapy. Radiother Oncol 71: 163-166, 2004.
21. Lester JF, Macbeth FR, Brewster AE, Court JB and Iqbal N: CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer 45: 237-242, 2004.
22. Nagy-Mignotte H, Bolla M, Wuyam B, Blanc-Jouvan F, Moro D, Brambilla C, Paramelle B, Vincent F, Kolodie H and Vrousos C: Sequential combination of 5-fluorouracil, cis-platinum and irradiation in unresectable non-small cell lung cancer. Radiother Oncol 15: 333-339, 1989.
23. Schwarzenberger P, Theodossiou C, Barron S, Diethelm L, Boyle M, Harrison L, Wynn RB, Salazar OM and Fariss A: Dose escalation of docetaxel concomitant with hypofractionated, once weekly chest radiotherapy for non-small-cell lung cancer: a phase I study. Am J Clin Oncol 27: 395-399, 2004.
24. Machtay M, Washam C and Devine P: Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer. Semin Oncol 32: S9-12, 2005.
25. Kjellstrom J, Kjellen E and Johnsson A: In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 44: 687-693, 2005.
26. Cappuzzo F, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, Lorusso V, Barbieri F, Castaldini L, Crucitta E, Marini L, Bartolini S, Scagliotti GV and Crino L: Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 93: 29-34, 2005.
27. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G and Bahlitzanakis N: Concurrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87: 385-392, 2002.
28. Cassatt DR, Fazenbaker CA, Kifle G and Bachy CM: Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol 30(Suppl): S31-39, 2003.